The Canadian company, which is working on a proposal priced at 11 euros per share, confirmed its interest in taking control of the blood products manufacturer.
Brookfield has asked for more time from the board Grifols for the study of public acquisition offer (takeover bid) that is being prepared about the company in alliance with the founding family, according to market sources.
Before it expires
To continue reading, use Premium
Try it for €1 the first month
and enjoy unlimited access to all Expansión web content
Or register with your Google account in two clicks